![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Preinitiation |
Unique ID issued by UMIN | UMIN000043288 |
Receipt No. | R000049422 |
Scientific Title | Effect of ingestion of fermented black maca-containing food "Aged black maca Macarhythm" on fatigue and QOL Placebo-controlled, double-blind, randomized, controlled trial |
Date of disclosure of the study information | 2022/06/17 |
Last modified on | 2021/02/09 |
Basic information | ||
Public title | Effect of ingestion of fermented black maca-containing food "Aged black maca Macarhythm" on fatigue and QOL
Placebo-controlled, double-blind, randomized, controlled trial |
|
Acronym | Effect of ingestion of fermented black maca-containing food "Aged black maca Macarhythm" on fatigue and QOL | |
Scientific Title | Effect of ingestion of fermented black maca-containing food "Aged black maca Macarhythm" on fatigue and QOL
Placebo-controlled, double-blind, randomized, controlled trial |
|
Scientific Title:Acronym | Effect of ingestion of fermented black maca-containing food "Aged black maca Macarhythm" on fatigue and QOL | |
Region |
|
Condition | ||
Condition | healthy individuals | |
Classification by specialty |
|
|
Classification by malignancy | Others | |
Genomic information | NO |
Objectives | |
Narrative objectives1 | For male and female subjects who are tired on a daily basis, we will continue to ingest fermented black maca-containing foods for 4 weeks and examine the effects on fatigue and QOL. |
Basic objectives2 | Efficacy |
Basic objectives -Others | |
Trial characteristics_1 | |
Trial characteristics_2 | |
Developmental phase |
Assessment | |
Primary outcomes | CFS (Chalder Fatigue Scale)
Fatigue VAS QOLVAS Athens Insomnia Scale OSA sleep questionnaire Urine frequency |
Key secondary outcomes |
Base | |
Study type | Interventional |
Study design | |
Basic design | Cross-over |
Randomization | Randomized |
Randomization unit | Individual |
Blinding | Double blind -all involved are blinded |
Control | Placebo |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | ||
No. of arms | 2 | |
Purpose of intervention | Prevention | |
Type of intervention |
|
|
Interventions/Control_1 | Ingestion of study food for 4 weeks | |
Interventions/Control_2 | Ingestion of control food substance for 4 weeks | |
Interventions/Control_3 | ||
Interventions/Control_4 | ||
Interventions/Control_5 | ||
Interventions/Control_6 | ||
Interventions/Control_7 | ||
Interventions/Control_8 | ||
Interventions/Control_9 | ||
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | (1) Subjects of men and women aged 20 to 80
(2) Subjects who are tired on a daily basis (3) Subjects who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing. |
|||
Key exclusion criteria | (1) Subjects with a history of liver disease, renal disease, digestive system disease, heart disease, respiratory disease, peripheral angiopathy, and other diseases that may affect the results of this study, or subjects with a history of surgery
(2) Subjects with diseases currently being treated (3) Subjects who have been diagnosed with psychiatric disorders such as chronic insomnia, depression, anxiety disorders, and schizophrenia (4) Subjects with food and drug allergies (5) Subjects on a diet (6) Subjects with irregular lives (7) Subjects who cannot stop taking health foods (including foods for specified health use and foods with functional claims) and quasi-drugs during the test period (8) Subjects who are continuously taking medicines (including OTC and prescription medicines) (9) Subjects taking excessive alcohol intake (10) Subjects who cannot stop drinking from the day before the test to the day of the test (11) Pregnant, lactating, or prospective pregnant or lactating subjects during the study period (12) Subjects who are participating in or will participate in other clinical trials at the start of this study, and within 4 weeks after the end of the study. (13) Other subjects judged by the investigator to be inappropriate |
|||
Target sample size | 30 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | Miura Clinic, Medical Corporation Kanonkai | ||||||
Division name | Internal Medicine | ||||||
Zip code | 530-0044 | ||||||
Address | Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka | ||||||
TEL | 0661355200 | ||||||
info@miura-cl.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | Oneness Support Co., Ltd. | ||||||
Division name | Clinical Trial Division | ||||||
Zip code | 530-0044 | ||||||
Address | Higashitenma building 4F, 1-7-17, Higashitenma, Kita-ku, Osaka | ||||||
TEL | 0648018917 | ||||||
Homepage URL | |||||||
mterashima@oneness-sup.co.jp |
Sponsor | |
Institute | Miura Clinic, Medical Corporation Kanonkai |
Institute | |
Department |
Funding Source | |
Organization | Fraijeu Co., Ltd. |
Organization | |
Division | |
Category of Funding Organization | Profit organization |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | Miura Clinic, Medical Corporation Kanonkai IRB |
Address | Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka |
Tel | 0661355200 |
mterashima@miura-cl.jp |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions | 医療法人花音会みうらクリニック(大阪府) Miura Clinic, Medical Corporation Kanonkai(Osaka) |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Preinitiation | ||||||
Date of protocol fixation |
|
||||||
Date of IRB |
|
||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049422 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |